RVMD
SLS
The market loves a good spillover story
SELLAS Life Sciences got a nice jolt on Thursday after Revolution Medicines scored an FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic adenocarcinoma. In biotech land, one company’s win can turn into everybody else’s audition — and SELLAS, which is working on SLS009, clearly caught some of that glow.
Why traders cared
The logic is pretty simple: if one RAS-pathway cancer drug can make it through the FDA, investors start squinting at every adjacent program like it’s the next Marvel cameo. SELLAS says SLS009 has shown preclinical activity in pancreatic cancer cells that are tough on leading RAS inhibitors, and that data is expected to show up at an upcoming medical conference.
What else SELLAS threw in the mix
This wasn’t just a “look over there!” moment. The company also highlighted progress in its 80-patient Phase 2 study in newly diagnosed AML patients who may not get much benefit from standard AZA/VEN treatment.
- Topline data from that study is expected in Q4 2026.
- SELLAS also said the treatment lowered MCL-1 and survivin levels.
- Shares were up 10.38% to $15.15 on Thursday, according to Benzinga Pro.
Big picture
SELLAS didn’t announce an FDA breakthrough of its own here, but biotech stocks don’t always need one. Sometimes all it takes is a neighbor’s approval and a promising pipeline sentence to get the market feeling a little more generous.